The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2-dimethyl-, 1,2-diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat

被引:75
作者
Fredenburg, AM
Sethi, RK
Allen, DD
Yokel, RA
机构
[1] UNIV KENTUCKY, GRAD CTR TOXICOL, LEXINGTON, KY 40536 USA
[2] UNIV KENTUCKY, MED CTR, COLL PHARM, LEXINGTON, KY 40536 USA
关键词
3-hydroxypyridin-4-ones 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one 1,2-dimethyl-3-hydroxypyridin-4-one; 1,2-diethyl-3-hydroxypyridin-4-one; blood-brain barrier; chelator; CP20; CP40; CP94; EL1NEt; L1; deferiprone;
D O I
10.1016/0300-483X(95)03301-U
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The 3-hydroxypyridin-4-ones (HPs) are iron and aluminium chelators. Their ability to enter the brain had not previously been directly determined. To determine whether they cross the blood-brain barrier (BBB), three HPs possessing a wide range of lipophilicity were examined: 1-[ethan-1'ol]-2-methyl-HP (CP40), 1,2-dimethyl-HP (CP20, L1, deferiprone), and 1,2-diethyl-HP (CP94, EL1NEt). Their pharmacokinetics were determined in rats to establish dosing parameters for microdialysis studies of BBB permeation. Studies were then conducted with microdialysis probes in the blood, frontal cortex, and lateral ventricle to determine the rate and extent of HP BBB permeability, All three HPs were detectable in brain dialysate samples collected 0-7 min after HP injection, demonstrating rapid entry into the brain, The extent of unbound distribution (an indicator of the mechanism of BBB permeation) was 0.9 and 1.2 for the frontal cortex and lateral ventricle for CP20, and was 1.1 and 1.6 for CP94, suggesting diffusion across the BBB, The extent of unbound distribution of CP40 was 0.2 for both the frontal cortex and lateral ventricle, suggesting the presence of a transporter moving it out of brain extracellular fluid. Introduction of cyanide into the brain did not affect the brain to blood CP40 ratio, suggesting that the transporter is not energy-dependent. Both CP94 and CP40 caused death due to respiratory failure, whereas CP20 did not. The ability of less toxic bidentate HP chelators, such as CP20, to enter the brain may enable their use in the treatment of metal-induced diseases and iron-facilitated oxidative injury involving the central nervous system.
引用
收藏
页码:191 / 199
页数:9
相关论文
共 32 条
[1]
ALUMINUM TOXICITY IN PATIENTS WITH CHRONIC-RENAL-FAILURE [J].
ALFREY, AC .
THERAPEUTIC DRUG MONITORING, 1993, 15 (06) :593-597
[2]
4-TRIMETHYLAMMONIUM ANTIPYRINE - A QUATERNARY AMMONIUM NONRADIONUCLIDE MARKER FOR BLOOD-BRAIN-BARRIER INTEGRITY DURING INVIVO MICRODIALYSIS [J].
ALLEN, DD ;
CROOKS, PA ;
YOKEL, RA .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1992, 28 (03) :129-135
[3]
DISSIMILAR ALUMINUM AND GALLIUM PERMEATION OF THE BLOOD-BRAIN-BARRIER DEMONSTRATED BY INVIVO MICRODIALYSIS [J].
ALLEN, DD ;
YOKEL, RA .
JOURNAL OF NEUROCHEMISTRY, 1992, 58 (03) :903-908
[4]
EVIDENCE FOR ENERGY-DEPENDENT TRANSPORT OF ALUMINUM OUT OF BRAIN EXTRACELLULAR FLUID [J].
ALLEN, DD ;
ORVIG, C ;
YOKEL, RA .
TOXICOLOGY, 1995, 98 (1-3) :31-39
[5]
REVERSAL OF ALUMINUM DIALYSIS ENCEPHALOPATHY AFTER DESFERRIOXAMINE TREATMENT [J].
ARZE, RS ;
PARKINSON, IS ;
CARTLIDGE, NEF ;
BRITTON, P ;
WARD, MK .
LANCET, 1981, 2 (8255) :1116-1116
[6]
BERGERON RJ, 1992, BLOOD, V79, P1882
[7]
SYNTHESIS, PHYSICOCHEMICAL PROPERTIES, AND BIOLOGICAL EVALUATION OF N-SUBSTITUTED 2-ALKYL-3-HYDROXY-4(1H)-PYRIDINONES - ORALLY-ACTIVE IRON CHELATORS WITH CLINICAL POTENTIAL [J].
DOBBIN, PS ;
HIDER, RC ;
HALL, AD ;
TAYLOR, PD ;
SARPONG, P ;
PORTER, JB ;
XIAO, GY ;
VANDERHELM, D .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (17) :2448-2458
[8]
EPEMOLU OR, 1992, DRUG METAB DISPOS, V20, P736
[9]
FOX JL, 1989, RSTRIP PHARMK STRIPP
[10]
FREDENBURG AM, 1993, DRUG METAB DISPOS, V21, P255